Canaan Has Capital For Start-Ups With Eye On New Twists On Traditional Modalities In Pharma

VC partner Colleen Cuffaro talked to Scrip about how the investment firm plans to direct investment in biopharma and raising capital in a challenging environment.

money bags
Canaan has raised capital for a new fund to invest in biopharma • Source: Shutterstock

Canaan Partners will invest $650m in health care and technology start-ups as part of a new, oversubscribed fund called Canaan XIII, the VC firm announced on 6 April. About 35% of the money, which will be dedicated to entrepreneurs seeking seed and series A financing, will be devoted to investment in biopharma.

An additional $200m of commitments is available to existing portfolio companies across all of Canaan’s active funds, with a similar...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Financing

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.